

Sub
R¹
cont.
M

said compound or its salt thereof, wherein Q is Q² (where Q² represents a single bond), Q⁶², Q⁶³, Q⁶⁴, Q³ (where R⁸ has the same meaning as defined above), Q⁴ (where R⁸ has the same meaning as defined above), Q¹⁷ (where R⁷ has the same meaning as defined above), Q³² (where R⁷ has the same meaning as defined above) or Q²⁷ (where R⁷ has the same meaning as defined above).

✓4. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of said compound or a salt thereof, wherein X¹ is -Ar-A-R¹ (wherein Ar, A and R¹ have the same meanings as defined above) and X² is a hydrogen atom.

✓5. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of said compound or a salt thereof, wherein X¹ is a hydrogen atom and X² is -Ar-A-R¹ (wherein Ar, A and R¹ have the same meanings as defined above).

✓6. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of said compound or a salt thereof, wherein the dashed line forms a single bond together with the solid line.

✓7. (Amended) The compound according to claim 1, a

pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein the steric configuration of X^1 in 11-position is β -configuration.

✓ 8. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein the steric configuration of X^2 in 7-position is α -configuration.

✓ 9. (Amended) The compound according to claim 2, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein Z is a straight-chained or branched alkyl group having 1 - 10 carbon atoms which optionally is substituted by a halogen atom.

✓ 11. (Amended) The compound according to claim 2, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein J is a single bond.

✓ 12. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein Ar is a single bond.

✓ 13. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein A is a methylene group.

~~14. (Amended) The compound according to claim 2, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein Q is Q⁶², Q⁶³ or Q⁶⁴.~~

~~15. (Amended) The compound according to claim 2, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein Q is Q³ where R⁸ is a hydrogen atom or Q⁴ where R⁸ is a hydrogen atom.~~

~~16. (Amended) The compound according to claim 2, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein Q is Q¹⁷ where R⁷ is a hydrogen atom, Q³² where R⁷ is a hydrogen atom or Q²⁷ where R⁷ is a hydrogen atom.~~

~~17. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein Ar is an aromatic hydrocarbon group and A is -O-.~~

~~18. (Amended) The compound according to claim 2, a pharmaceutically acceptable salt thereof, or a prodrug of the compound or its salt, wherein G is an optionally substituted straight-chained alkylene group having 2 - 15 carbon atoms.~~

~~23. (Amended) The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a prodrug of the~~

compound or its salt, which is selected from the group consisting of

17 β -hydroxy-7 α -{7-(N,N-dimethylaminocarbonyl)heptyl}-5 α -androstan-3-one;

17 β -hydroxy-7 α -{7-(N-ethylaminocarbonyl)heptyl}-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-(isopropylaminocarbonyl)heptyl)-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-methyl-N-butylaminocarbonyl)heptyl]-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N,N-diethylaminocarbonyl)heptyl]-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(piperidinocarbonyl)heptyl]-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-{N-(2-furylmethyl)aminocarbonyl}heptyl]-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-{7-(N-methylaminocarbonyl)heptyl}-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-methyl-N-ethylaminocarbonyl)heptyl]-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-methyl-N-propylaminocarbonyl)heptyl]-5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-methyl-N-isopropylaminocarbonyl)heptyl]-

5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-methyl-N-benzylaminocarbonyl)heptyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[7-(1-pyrrolidinylcarbonyl)heptyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[7-(morpholinocarbonyl)heptyl]-5 α -androstan-3-
one;

17 β -hydroxy-7 α -[9-(N,N-dimethylaminocarbonyl)nonyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[9-(N,N-diethylaminocarbonyl)nonyl]-5 α -
androstan-3-one;

A3 17 β -hydroxy-7 α -[9-(N-methyl-N-butylaminocarbonyl)nonyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[9-(N-methyl-N-propylaminocarbonyl)nonyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[9-(morpholinocarbonyl)nonyl]-5 α -androstan-3-
one;

17 β -hydroxy-7 α -[10-(N,N-dimethylaminocarbonyl)decyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[7-(N-(2-hydroxyethyl)aminocarbonyl)heptyl]-
5 α -androstan-3-one;

17 β -hydroxy-7 α -[7-(N-propylaminocarbonyl)heptyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[7-(N-benzylaminocarbonyl)heptyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[7-(N-(2-phenylethyl)aminocarbonyl)heptyl]-5 α -
androstan-3-one;

17 β -hydroxy-11 β -[9-(N,N-diethylaminocarbonyl)nonyl]-5 α -
androstan-3-one;

17 β -hydroxy-7 α -[3-[3-{3-(N-
methylaminocarbonyl)propoxy}phenyl]propyl]-5 α -androstan-3-
one;

17 β -hydroxy-7 α -[3-[3-{3-(N,N-
dimethylaminocarbonyl)propoxy}phenyl]propyl]-5 α -androstan-3-
one; and

17 β -hydroxy-7 α -[3-[3-{4-(1-
pyrrolidinylcarbonyl)butoxy}phenyl]propyl]-5 α -androstan-3-
one.

REMARKS

The above amendments are made to eliminate improper multi-dependencies and make the claims consistent with 37 CFR 1.75(c) to ensure examination of all of the claims. The amendments are not "narrowing" amendments. The scope of the claims has not been changed; no limitations have been added and none are intended.